Clinically, loss-of-function mutations in APC are observed in 90% of patients with CRC, and these mutations contribute to aberrant activation of the β-catenin-PKM2 regulatory axis, thereby sustaining tumor growth through enhanced glycolytic metabolism (27). The gene discussed is PKM; the disease is neoplasm.